Nastassia Samal
Kura Oncology (NASDAQ:KURA) stock slid 17% post-market after the company announced a collaboration deal with Japan’s Kyowa Kirin (OTCPK:KNBWY) for its leukemia drug candidate ziftomenib worth up to $1.53B, plus profits from potential sales.
Under the deal, Kura (KURA